SUPN Supernus Pharmaceuticals Inc

Price (delayed)

$43.39

Market cap

$2.52B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.92

Enterprise value

$2.37B

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 34
Relative Valuation: Rel. Valuation: 16
Relative Profitability: Rel. Profitability: 27

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ...

Highlights
Supernus Pharmaceuticals's revenue has increased by 25% YoY and by 7% from the previous quarter
The gross profit is up by 24% YoY and by 5% QoQ
The quick ratio has contracted by 28% YoY but it has grown by 11% from the previous quarter
The debt is up by 21% year-on-year but it is down by 2.8% since the previous quarter
Supernus Pharmaceuticals's equity has decreased by 4.2% QoQ and by 3.1% YoY

Key stats

What are the main financial stats of SUPN

SUPN stock price

How has the Supernus Pharmaceuticals stock price performed over time
Intraday
-0.82%
1 week
4.86%
1 month
-5.37%
1 year
-7.35%
YTD
-12.7%
QTD
-6.71%

Financial performance

How have Supernus Pharmaceuticals's revenue and profit performed over time
Revenue
$830.44M
Gross profit
$731.41M
Operating income
-$110.31M
Net income
-$109.89M
Gross margin
88.1%
Net margin
-13.2%
SUPN's operating income has plunged by 174% from the previous quarter
The company's operating margin has shrunk by 156% QoQ
Supernus Pharmaceuticals's revenue has increased by 25% YoY and by 7% from the previous quarter
The gross profit is up by 24% YoY and by 5% QoQ

Price vs fundamentals

How does SUPN's price correlate with its fundamentals

Growth

What is Supernus Pharmaceuticals's growth rate over time

Valuation

What is Supernus Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.44
P/S
3.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.85
SUPN's price to book (P/B) is 23% more than its 5-year quarterly average of 2.0 but 9% less than its last 4 quarters average of 2.7
Supernus Pharmaceuticals's equity has decreased by 4.2% QoQ and by 3.1% YoY
Supernus Pharmaceuticals's revenue has increased by 25% YoY and by 7% from the previous quarter
The P/S is 17% below the last 4 quarters average of 3.7 but 6% above the 5-year quarterly average of 2.9

Efficiency

How efficient is Supernus Pharmaceuticals business performance
SUPN's return on invested capital has dropped by 154% since the previous quarter
The return on sales has dropped by 132% since the previous quarter

Dividends

What is SUPN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SUPN.

Financial health

How did Supernus Pharmaceuticals financials performed over time
The quick ratio has contracted by 28% YoY but it has grown by 11% from the previous quarter
The company's total liabilities rose by 25% YoY but it fell by 6% QoQ
The debt is 97% smaller than the equity
Supernus Pharmaceuticals's debt to equity has soared by 50% YoY
The debt is up by 21% year-on-year but it is down by 2.8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.